Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation

A successful DNA vaccine for the treatment of tumors should break established immune tolerance to tumor antigen. However, due to the relatively low immunogenicity of DNA vaccines, compared to other kinds of vaccines using live virus or protein, a recombinant viral vector was used to enhance humoral...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, So Young, Kang, Dongxu, Choi, Hye Jin, Joo, Yeonsoo, Kim, Joo-Hang, Song, Jae J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362529/
https://www.ncbi.nlm.nih.gov/pubmed/28178658
http://dx.doi.org/10.18632/oncotarget.15008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362529/
https://www.ncbi.nlm.nih.gov/pubmed/28178658
http://dx.doi.org/10.18632/oncotarget.15008

Ejemplares similares